<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00698685</url>
  </required_header>
  <id_info>
    <org_study_id>05-0624-04</org_study_id>
    <secondary_id>R21CA106177</secondary_id>
    <secondary_id>05110</secondary_id>
    <secondary_id>UARIZ-05-0624-01</secondary_id>
    <secondary_id>UARIZ-SRC17920</secondary_id>
    <nct_id>NCT00698685</nct_id>
    <nct_alias>NCT00543283</nct_alias>
  </id_info>
  <brief_title>Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation</brief_title>
  <official_title>Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent®) and Alemtuzumab (Campath®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study tests the hypothesis that a purely immunosuppressive preparative regimen allows
      engraftment of related or unrelated allogeneic hematopoietic stem cells in subjects with
      high-risk malignancies, without causing the post-transplant myelosuppression (e.g.,
      neutropenia, thrombocytopenia) that occurs with currently used reduced-intensity
      (nonmyeloablative) preparative regimens. This study incorporates both safety and efficacy
      endpoints and evaluates a novel preparative regimen of alemtuzumab plus continuous-infusion
      pentostatin, two immunosuppressive agents with different mechanisms of action, in recipients
      of related or unrelated allogeneic hematopoietic stem cell transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives of the study:

        -  To determine the efficacy of a preparative regimen of pentostatin and alemtuzumab plus
           related or unrelated allogeneic peripheral blood stem cell transplantation (PBSCT) in
           inducing durable donor lymphohematopoietic cell chimerism (defined as at least 50% donor
           cells in the peripheral blood) by 100 days after PBSCT (day +100) in subjects with
           high-risk malignancies who are at high risk for morbidity and mortality with
           conventional intensive pre-transplant conditioning regimens.

        -  To determine the safety of a preparative regimen of pentostatin and alemtuzumab plus
           related or unrelated allogeneic PBSCT, as measured by the non-relapse mortality at day
           +100 in the study subject population.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Pentostatin/alemtuzumab regimen had greater risk of graft failure.
  </why_stopped>
  <start_date type="Actual">January 23, 2006</start_date>
  <completion_date type="Actual">April 26, 2011</completion_date>
  <primary_completion_date type="Actual">April 13, 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Actuarial Probability of Donor Hematopoietic Engraftment (Defined as at Least 50% Donor DNA in Bone Marrow at Day 100).</measure>
    <time_frame>Day 100 after transplant.</time_frame>
    <description>The number of participants with donor hematopoietic engraftment at day 100 is reported in the data table, and the actuarial probability is calculated using the Kaplan-Meier product-limit estimate statistic, as reported in the statistical analysis section below.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-relapse Mortality at or Before Day 100</measure>
    <time_frame>Day 100 after transplant</time_frame>
    <description>The primary safety outcome is indicated by the number of participants who died at or before Day 100 after transplant for any reason other than relapse of disease (Leukemia, Lymphoma, Hodgkin's disease, Hematologic Neoplasms, Multiple Myeloma, Renal Cell Carcinoma).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Hodgkin's Disease</condition>
  <condition>Hematologic Neoplasms</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Carcinoma, Renal Cell</condition>
  <arm_group>
    <arm_group_label>Preparative Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days - 8 through -6: pentostatin 4 mg/m2/24 hr as a continuous intravenous infusion (CIVI) (total cumulative dose, 12 mg/m2 over 3 days)
Days - 5 through - 1: alemtuzumab 20 mg per dose intravenously over 8 hours daily for 5 doses (total cumulative dose, 100 mg)
Followed by Allogeneic hematopoietic stem cell transplantation, related or unrelated donor, on day 0. Patients also receive cyclosporine intravenous (IV) continuously beginning on day -2, continuing (IV or orally) until day 100, followed by a taper.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentostatin</intervention_name>
    <description>Days - 8 through -6: pentostatin 4 mg/m2/24 hr as a continuous intravenous infusion (CIVI) (total cumulative dose, 12 mg/m2 over 3 days)</description>
    <arm_group_label>Preparative Regimen</arm_group_label>
    <other_name>Nipent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <description>Days - 5 through - 1: alemtuzumab 20 mg per dose intravenously over 8 hours daily for 5 doses (total cumulative dose, 100 mg)</description>
    <arm_group_label>Preparative Regimen</arm_group_label>
    <other_name>Campath</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Infusion of related or unrelated donor peripheral blood progenitor cells on day 0.</description>
    <arm_group_label>Preparative Regimen</arm_group_label>
    <other_name>HSCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        One of these diagnoses:

          -  Acute myeloid leukemia in complete or partial remission

          -  Acute lymphocytic leukemia in complete or partial remission

          -  Chronic myeloid leukemia in first or subsequent chronic phase or accelerated phase

          -  Chronic lymphocytic leukemia that has recurred or failed after at least one course of
             front-line therapy

          -  Hodgkin's disease or non-Hodgkin's lymphoma that has failed front-line therapy, is in
             second or subsequent remission, or is in chemosensitive relapse

          -  Multiple myeloma that is in complete or partial remission or in chemosensitive relapse

          -  Myelodysplastic Syndrome classified as intermediate-2 or high risk according to
             International Prognostic Scoring System

          -  Metastatic renal cell carcinoma that has failed at least one previous front-line
             chemotherapy and/or biological therapy regimen and that is radiographically detectable
             and evaluable

          -  Treatment with at least one previous course of chemotherapy or biological therapy for
             the malignancy for which allogeneic PBPCT is being considered (i.e., a subject cannot
             be enrolled on this study for initial treatment of a malignancy).

        AND at least one of the following:

          -  Age 50 years or older.

          -  Previous transplant with autologous or allogeneic hematopoietic cells (peripheral
             blood, bone marrow, or placental blood).

          -  High-risk status of hematologic malignancy, i.e., not in first complete remission or
             first chronic phase.

          -  Presence of other medical condition that could place subject at unacceptably high risk
             of regimen-related mortality such as documented chronic bronchitis or emphysema;
             decreased cardiac ejection fraction (but with ejection fraction at least 30%), or
             history of coronary artery disease; renal insufficiency (but with creatinine clearance
             at least 30 mL/min); hepatic cirrhosis (but with normal hepatic synthetic function);
             or documented or presumed invasive fungal infection requiring treatment with
             intravenous antifungal agent(s).

        Exclusion Criteria:

          -  Eligibility for another clinical therapeutic protocol or standard-of-care treatment
             that offers higher probability of cure or long-term control of subject's malignancy.

          -  Progressive Hodgkin's disease, non-Hodgkin's lymphoma, Hodgkin disease or multiple
             myeloma that is refractory to salvage chemotherapy.

          -  Acute leukemia (AML or ALL) in relapse, CML in blast phase/blast crisis, or MDS with
             greater than 30% marrow involvement (MDS-AML). Subjects with these disease
             characteristics may be considered for this study if complete or partial remissions
             (CRs or PRs) occur after salvage chemotherapy.

          -  Severe organ dysfunction, such as: cardiac ejection fraction below 30% or symptomatic
             ischemic cardiac disease; creatinine clearance below 30 mL/min; carbon monoxide
             diffusing capacity (DLCO) below 35% and/or need for supplemental oxygen; severe
             hepatic cirrhosis with ascites and/or varices; hepatic dysfunction associated with
             abnormal synthetic function (e.g., coagulopathy) and/or bilirubin greater than two
             times upper limit of normal and/or transaminases (AST or ALT) above four times upper
             limit of normal.

          -  Untreated or progressive central nervous system involvement by malignancy

          -  Subject is pregnant or breast-feeding.

          -  Karnofsky score below 50

          -  Seropositivity for human immunodeficiency virus (HIV).

          -  Life expectancy less than 12 weeks with conventional treatments.

          -  For subjects who are fertile, refusal to practice contraception upon entering this
             study and for at least 12 months after PBPCT or after cessation of immunosuppressive
             treatments (e.g., cyclosporine), whichever occurs later.

          -  Failure to obtain at least 5.0 x 106 allogeneic donor CD34+ cells per kg of recipient
             weight in PBPC product.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew M Yeager, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Cancer Center at UMC North/University Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Cancer Center at UMC North</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2008</study_first_submitted>
  <study_first_submitted_qc>June 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2008</study_first_posted>
  <results_first_submitted>December 28, 2010</results_first_submitted>
  <results_first_submitted_qc>January 10, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 12, 2011</results_first_posted>
  <last_update_submitted>March 23, 2017</last_update_submitted>
  <last_update_submitted_qc>March 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allogeneic Hematopoietic Cell Transplantation</keyword>
  <keyword>Preparative Regimen</keyword>
  <keyword>Pentostatin</keyword>
  <keyword>Alemtuzumab</keyword>
  <keyword>Hodgkin Disease and Lymphoma, non-Hodgkin</keyword>
  <keyword>leukemia, myeloid, acute</keyword>
  <keyword>leukemia, lymphocytic, acute</keyword>
  <keyword>leukemia, myeloid, chronic</keyword>
  <keyword>leukemia, lymphocytic, chronic</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Myelodysplastic Syndromes</keyword>
  <keyword>Carcinoma, Renal Cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Pentostatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Following University of Arizona IRB review and approval, the study opened to accrual on November 2005 at the Arizona Cancer Center clinic and University Medical Center sites [Tucson, Arizona].</recruitment_details>
      <pre_assignment_details>Following consent process, subjects who consented to participate were screened per the selection criteria in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Preparative Regimen of Pentostatin and Alemtuzumab</title>
          <description>Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic [related or unrelated] Hematopoietic SCT.
Pentostatin: 4 mg/m2/24 hour IV continuously over 72 hours on days -8 to -6. Alemtuzumab: 20 mg per dose IV over 8 hours on days -5 to -1. Patients then received infusion of related or unrelated donor peripheral blood progenitor cells on day 0. Patients also receive cyclosporine IV continuously beginning on day -2, continuing (IV or orally) until day 100, followed by a taper.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Sister withdrew as donor</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Off study pre transplant by clinic MD</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Preparative Regimen of Pentostatin and Alemtuzumab</title>
          <description>Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic [related or unrelated] Hematopoietic SCT.
Pentostatin: 4 mg/m2/24 hour IV continuously over 72 hours on days -8 to -6. Alemtuzumab: 20 mg per dose IV over 8 hours on days -5 to -1. Patients then received infusion of related or unrelated donor peripheral blood progenitor cells on day 0. Patients also receive cyclosporine IV continuously beginning on day -2, continuing (IV or orally) until day 100, followed by a taper.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Actuarial Probability of Donor Hematopoietic Engraftment (Defined as at Least 50% Donor DNA in Bone Marrow at Day 100).</title>
        <description>The number of participants with donor hematopoietic engraftment at day 100 is reported in the data table, and the actuarial probability is calculated using the Kaplan-Meier product-limit estimate statistic, as reported in the statistical analysis section below.</description>
        <time_frame>Day 100 after transplant.</time_frame>
        <population>All participants who completed treatment and underwent allogeneic transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>Preparative Regimen of Pentostatin and Alemtuzumab</title>
            <description>Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic [related or unrelated] Hematopoietic SCT.
Pentostatin: 4 mg/m2/24 hour IV continuously over 72 hours on days -8 to -6. Alemtuzumab: 20 mg per dose IV over 8 hours on days -5 to -1. Patients then received infusion of related or unrelated donor peripheral blood progenitor cells on day 0. Patients also receive cyclosporine IV continuously beginning on day -2, continuing (IV or orally) until day 100, followed by a taper.</description>
          </group>
        </group_list>
        <measure>
          <title>Actuarial Probability of Donor Hematopoietic Engraftment (Defined as at Least 50% Donor DNA in Bone Marrow at Day 100).</title>
          <description>The number of participants with donor hematopoietic engraftment at day 100 is reported in the data table, and the actuarial probability is calculated using the Kaplan-Meier product-limit estimate statistic, as reported in the statistical analysis section below.</description>
          <population>All participants who completed treatment and underwent allogeneic transplant.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>actuarial probability of engraftment</param_type>
            <param_value>70</param_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Actuarial probability of engraftment at day +100 is calculated according to the product-limit estimate method.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Non-relapse Mortality at or Before Day 100</title>
        <description>The primary safety outcome is indicated by the number of participants who died at or before Day 100 after transplant for any reason other than relapse of disease (Leukemia, Lymphoma, Hodgkin’s disease, Hematologic Neoplasms, Multiple Myeloma, Renal Cell Carcinoma).</description>
        <time_frame>Day 100 after transplant</time_frame>
        <population>All participants who received at least 1 day of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Preparative Regimen of Pentostatin and Alemtuzumab</title>
            <description>Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic [related or unrelated] Hematopoietic SCT.
Pentostatin: 4 mg/m2/24 hour IV continuously over 72 hours on days -8 to -6. Alemtuzumab: 20 mg per dose IV over 8 hours on days -5 to -1. Patients then received infusion of related or unrelated donor peripheral blood progenitor cells on day 0. Patients also receive cyclosporine IV continuously beginning on day -2, continuing (IV or orally) until day 100, followed by a taper.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-relapse Mortality at or Before Day 100</title>
          <description>The primary safety outcome is indicated by the number of participants who died at or before Day 100 after transplant for any reason other than relapse of disease (Leukemia, Lymphoma, Hodgkin’s disease, Hematologic Neoplasms, Multiple Myeloma, Renal Cell Carcinoma).</description>
          <population>All participants who received at least 1 day of treatment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data for this study was collected from January 23, 2006 to April 13, 2009.</time_frame>
      <desc>Adverse event data was collected and entered into the AZCC database which is password protected. The safety population is defined to be all participants who completed at least 1 day of treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Preparative Regimen of Pentostatin and Alemtuzumab</title>
          <description>Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic [related or unrelated] Hematopoietic SCT.
Pentostatin: 4 mg/m2/24 hour IV continuously over 72 hours on days -8 to -6. Alemtuzumab: 20 mg per dose IV over 8 hours on days -5 to -1. Patients then received infusion of related or unrelated donor peripheral blood progenitor cells on day 0. Patients also receive cyclosporine IV continuously beginning on day -2, continuing (IV or orally) until day 100, followed by a taper.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>metabolic/laboratory: elevated AST and ALT</sub_title>
                <description>These blood chemistries returned to normal within several days after cessation of pentostatin infusion and without specific intervention: probably associated with the infusion of pentostatin.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>hyperbilirubinemia</sub_title>
                <description>Due to progressive hepatic infiltration by Hodgkin's disease and felt to be an expected SAE that was related to subject's aggressive underlying malignancy and unrelated to investigational treatment.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death on study, post BMT</sub_title>
                <description>Cardiac and respiratory failure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>altered mental status and progressive obtundation [disseminated toxoplasmosis]</sub_title>
                <description>After extensive evaluation, determined subject had disseminated toxoplasmosis. Subject died shortly after initiation of definitive therapy for toxoplasmosis. Assessed expected SAE [infections] and possibly related to investigational treatment.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>disseminated toxoplasmosis</sub_title>
                <description>Subject had persistent fevers and disseminated toxoplasmosis determined by quantitative PCR on a blood sample. Assessed as expected SAE (infections)and possibly related to investigational treatment.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>hemorrhagic cystitis associated with BK virus</sub_title>
                <description>Developed about 50 days after unrelated PBPCT;required hospital stay for continuous bladder irrigation and transfusions of red cells and platelets; also had elective cystoscopy, at which time clot was evacuated from the bladder. Possibly related.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>thrombotic microangiopathy</sub_title>
                <description>Developed in May 2009 about 6 months after administration of investigational treatment and required hemodialysis. Assessed as expected SAE and unrelated to the investigational treatment.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>hypoxia and dyspnea which was a result of pulmonary hemorrhage</sub_title>
                <description>Occurred without evidence of donor engraftment. subject had comorbidities [i.e., coronary artery disease] died with multisystem failure. Assessed as expected SAE and was possibly related.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/Bone Marrow</sub_title>
                <counts group_id="E1" events="63" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>DIC (disseminated intravascular coagulation)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Edema: viscera</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fibrinogen</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="36" subjects_affected="8" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lymphatics</sub_title>
                <counts group_id="E1" events="17" subjects_affected="8" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="35" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>PTT (Partial Thromboplastin Time)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac General</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Cardiac Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Cardiac troponin T (cTnT)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pericardial effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Death not associated with CTCAE term</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Ocular/Visual</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vision-photophobia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gastritis (including bile reflux gastritis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="33" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Heartburn/dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="22" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="12" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptoms</sub_title>
                <counts group_id="E1" events="33" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &gt;1.0 x=&quot;&quot; 10e9=&quot;&quot;/L)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="98" subjects_affected="12" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Allergy/Immunology</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Autoimmune reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Colitis, infectious (e.g., Clostridium difficile)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="20" subjects_affected="8" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis (metabolic or respiratory)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase, increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase), increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase), increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bicarbonate, serum-low</sub_title>
                <counts group_id="E1" events="10" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Creatinine, increased</sub_title>
                <counts group_id="E1" events="18" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" events="36" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-low (hypomagnesemia)</sub_title>
                <counts group_id="E1" events="40" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory</sub_title>
                <counts group_id="E1" events="84" subjects_affected="10" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Phosphate, serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Potassium, serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" events="19" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sodium, serum-high (hypernatremia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Uric acid, serum-high (hyperuricemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Extrapyramidal/involuntary movement/restlessness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Mood alteration</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neurology</sub_title>
                <counts group_id="E1" events="14" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Speech impairment (e.g., dysphasia or aphasia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary</sub_title>
                <description>Hematuria, anuria, renal insufficiency, urinary tract infection.</description>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urinary retention (including neurogenic bladder)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory</sub_title>
                <counts group_id="E1" events="28" subjects_affected="7" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cytokine release syndrome/acute infusion reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dermatology/Skin</sub_title>
                <counts group_id="E1" events="18" subjects_affected="8" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash: erythema multiforme (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage/Bleeding</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/embolism (vascular access-related)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vascular</sub_title>
                <description>Increased [cyclosporine] CSA level, jugular venous distention, port occlusion [2].</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We did not meet criteria to stop the study because of nonrelapse mortality (safety endpoint). However, we stopped accrual to the study because of failure to meet minimal criteria for engraftment (efficacy endpoint).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Andrew M. Yeager, MD</name_or_title>
      <organization>University of Arizona, Arizona Cancer Center</organization>
      <phone>520-626-0662</phone>
      <email>ayeager@azcc.arizona.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

